Index additions put Indivior Pharmaceuticals in the spotlight
Indivior Pharmaceuticals (INDV) has been added to the Russell 2000 Growth-Defensive, Value-Defensive, and Defensive indices, an event that can influence trading activity as index funds adjust their holdings.
See our latest analysis for Indivior Pharmaceuticals.
At a share price of US$40.83, Indivior Pharmaceuticals has seen a 90 day share price return of 27.83% and a 1 year total shareholder return of 169.15%. This suggests momentum has been strong as the recent Russell 2000 index additions draw extra attention from institutional investors.
If this kind of index driven move has you looking for other ideas, it could be a good moment to scan the market using our screener for 40 healthcare AI stocks.
After such a sharp move and with fresh index demand in play, the key question for Indivior Pharmaceuticals is whether the current US$40.83 share price still offers sufficient potential reward relative to the risks involved, given what the valuation now implies.
Most Popular Narrative: 30% Undervalued
Compared with the last close at $40.83, the most followed narrative pegs Indivior Pharmaceuticals' fair value at about $58.33, implying a wide gap in expectations.
The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026. This plan is expected to reduce nonessential spend by at least US$150 million a year and cap 2026 operating expenses at US$450 million, which directly supports adjusted EBITDA growth and free cash flow.
Want to see what kind of revenue profile and profit margins sit behind that fair value jump? The narrative leans on tighter costs, higher earnings and a lower future earnings multiple than many peers.
Based on this narrative, the valuation work uses a 7.11% discount rate to bring future earnings back to today, with assumptions about revenue growth, margin expansion and share count reductions all feeding into the $58.33 figure. Result: Fair Value of $58.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Indivior Pharmaceuticals still faces execution risk if SUBLOCADE adoption in long acting injectables stalls, and if cost cuts end up limiting commercial support or future growth options.
Find out about the key risks to this Indivior Pharmaceuticals narrative.
Another View: Indivior Pharmaceuticals Through Its P/E Ratio
The earlier fair value work presents Indivior Pharmaceuticals as materially undervalued. However, the P/E ratio tells a more cautious story. At 19.8x it sits slightly above its fair ratio of 19.4x and the US pharmaceuticals average of 15.3x, while trading below the peer average of 27.7x. That mix hints at both some valuation support and some downside risk if sentiment cools, so it raises the question of which signal carries more weight.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Some of this may sound optimistic and some cautious. Move quickly to review the underlying metrics, weigh both sides, and check the 4 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Indivior Pharmaceuticals?
If the Indivior Pharmaceuticals story has sharpened your focus, do not stop here. Broaden your watchlist with other opportunities that could fit your style.
- Spot potential value candidates by scanning 45 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their profiles.
- Strengthen your focus on resilience by reviewing 74 resilient stocks with low risk scores that score well on financial health and business stability.
- Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems before they sit firmly on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com